Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide

被引：0
|
作者：
Jonas Kildegaard
Stephen T. Buckley
Rasmus H. Nielsen
Gro K. Povlsen
Torben Seested
Ulla Ribel
Helle B. Olsen
Svend Ludvigsen
Claus B. Jeppesen
Hanne H. F. Refsgaard
Kristian M. Bendtsen
Niels R. Kristensen
Susanne Hostrup
Jeppe Sturis
机构：
[1] Novo Nordisk A/S,
来源：
Pharmaceutical Research | 2019年 / 36卷
关键词：
absorption; fast-acting insulin aspart; niacinamide; oligomerization; vasodilation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Fast-acting insulin in snail venom
    Le Bras, Alexandra
    LAB ANIMAL, 2019, 48 (04) : 113 - 113
  • [42] Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
    Hanne Haahr
    Thomas R. Pieber
    Chantal Mathieu
    Theis Gondolf
    Masanari Shiramoto
    Lars Erichsen
    Tim Heise
    Clinical Pharmacokinetics, 2019, 58 : 639 - 649
  • [43] The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
    Leelarathna, Lalantha
    Ashley, Donna
    Fidler, Carrie
    Parekh, Witesh
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (07) : 187 - 197
  • [44] Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study
    Wendy Lane
    Mads Faurby
    Lise Lotte N. Husemoen
    Dmitriy L. Markovich
    Naveen Rathor
    Christophe De Block
    Diabetes Therapy, 2021, 12 : 3067 - 3077
  • [45] The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes
    Biester, Torben
    von Dem Berge, Thekla
    Bendtsen, Line Quist
    Bendtsen, Mette Dahl
    Rathor, Naveen
    Danne, Thomas
    Haahr, Hanne
    PEDIATRIC DIABETES, 2020, 21 (05) : 781 - 790
  • [46] Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart
    Basu, Ananda
    Pieber, Thomas R.
    Hansen, Ann K.
    Sach-Friedl, Stefanie
    Erichsen, Lars
    Basu, Rita
    Haahr, Hanne
    DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1615 - 1622
  • [47] Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study
    Lane, Wendy
    Faurby, Mads
    Husemoen, Lise Lotte N.
    Markovich, Dmitriy L.
    Rathor, Naveen
    De Block, Christophe
    DIABETES THERAPY, 2021, 12 (12) : 3067 - 3077
  • [48] Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
    Bode, Bruce W.
    Iotova, Violeta
    Kovarenko, Margarita
    Laffel, Lori M.
    Rao, Paturi V.
    Deenadayalan, Srikanth
    Ekelund, Magnus
    Larsen, Steffen Falgreen
    Danne, Thomas
    DIABETES CARE, 2019, 42 (07) : 1255 - 1262
  • [49] Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting
    Russell-Jones, David
    Heller, Simon R.
    Buchs, Sarah
    Sandberg, Anna
    Valentine, William J.
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1773 - 1780
  • [50] Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
    Havelund, Svend
    Ribel, Ulla
    Hubalek, Frantisek
    Hoeg-Jensen, Thomas
    Wahlund, Per-Olof
    Jonassen, Ib
    PHARMACEUTICAL RESEARCH, 2015, 32 (07) : 2250 - 2258
12345